Humane Genomics
YC S21New York City, US · Founded 2019 · 5 employees · 3 known investors
Humane Genomics develops oncolytic viral therapies designed to selectively target and kill cancer cells using engineered RNA viruses, particularly Vesicular Stomatitis Virus. The company leverages a computational platform for viral genome design and engineering to create cancer treatments with improved safety, efficacy, and manufacturing efficiency.
BiotechDeep TechHealthtechMedical DevicesHard TechSynthetic Biologyin /humanegenomics@weijmarshausen
Founders & leadership· Y Combinator alumni (S21)
Peter Weijmarshausenin𝕏Co-founder & CEO
Chad Molesin𝕏Founder
Investors · 3
In the news
- Humane Genomics – Matthew Mandelmatthewmandel.com · 2025
- Humane Genomics Raises Seed Fundingfinsmes.com · 2025
- Announcing our Series Seed financing - Humane Genomicshumanegenomics.com · 2025
- Humane Genomics is 3D-printing oncolytic viruses to treat rare cancers | FierceBiotechfiercebiotech.com · 2021
- Humane Genomics - 2025 Funding Rounds & List of Investors - Tracxntracxn.com · 2021
- Humane Genomics - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2021
- Team - Humane Genomicshumanegenomics.com · 2019